Theravance Biopharma, Inc. - TBPH
Insiders (Form 4) · last 180 days · showing up to 200 transactions
· Form 144 is shown in the SEC filings tab
· Updating…
Visible: 0
Transaction codes:
P = Open-market purchase ·
S = Open-market sale ·
A = Grant/award ·
M = Exercise/conversion of derivative ·
G = Gift ·
F = Tax withholding ·
J = Other ·
A/D:
A = Acquired (buy/receive) ·
D = Disposed (sell/give)
| Filed | Owner | Title | Code | A/D | Shares | Price | Value | Shares after | SEC |
|---|---|---|---|---|---|---|---|---|---|
| May 22, 2026 | SVP & CHIEF FINANCIAL OFFICER | F | D | 8,670.0 | 16.55 | 143,488.5 | 344,953.0 | View | |
| May 22, 2026 | SVP, DEV & HEAD OF IRE OFFICE | F | D | 6,827.0 | 16.55 | 112,986.85 | 177,334.0 | View | |
| May 22, 2026 | SVP, GEN COUNSEL AND SECRETARY | F | D | 8,829.0 | 16.55 | 146,119.95 | 363,120.0 | View | |
| May 22, 2026 | SVP, COMM & MEDICAL AFFAIRS | F | D | 5,678.0 | 16.55 | 93,970.9 | 245,771.0 | View | |
| May 22, 2026 | CHIEF EXECUTIVE OFFICER | F | D | 20,038.0 | 16.55 | 331,628.9 | 1,631,056.0 | View | |
| Apr 03, 2026 | SVP, COMM & MEDICAL AFFAIRS | A | A | 18,750.0 | 0.0 | 0.0 | 251,449.0 | View | |
| Apr 03, 2026 | SVP, GEN COUNSEL AND SECRETARY | A | A | 37,500.0 | 0.0 | 0.0 | 371,949.0 | View | |
| Apr 03, 2026 | SVP & CHIEF FINANCIAL OFFICER | A | A | 37,500.0 | 0.0 | 0.0 | 353,623.0 | View | |
| Apr 03, 2026 | CHIEF EXECUTIVE OFFICER | A | A | 75,000.0 | 0.0 | 0.0 | 1,651,094.0 | View | |
| Mar 18, 2026 | SVP, COMM & MEDICAL AFFAIRS | S | D | 7,766.0 | 13.9162 | 108,073.21 | 232,699.0 | View | |
| Mar 18, 2026 | SVP, COMM & MEDICAL AFFAIRS | S | D | 15,534.0 | 14.0 | 217,476.0 | 240,465.0 | View | |
| Mar 18, 2026 | SVP, COMM & MEDICAL AFFAIRS | S | D | 7,767.0 | 13.9163 | 108,087.9 | 255,999.0 | View | |
| Feb 24, 2026 | SVP, COMM & MEDICAL AFFAIRS | F | D | 13,929.0 | 19.66 | 273,844.14 | 263,766.0 | View | |
| Feb 24, 2026 | SVP, GEN COUNSEL AND SECRETARY | F | D | 20,833.0 | 19.66 | 409,576.78 | 334,449.0 | View | |
| Feb 24, 2026 | SVP, DEV & HEAD OF IRE OFFICE | F | D | 16,851.0 | 19.66 | 331,290.66 | 184,161.0 | View | |
| Feb 24, 2026 | SVP & CHIEF FINANCIAL OFFICER | F | D | 20,672.0 | 19.66 | 406,411.52 | 316,123.0 | View | |
| Feb 24, 2026 | CHIEF EXECUTIVE OFFICER | F | D | 74,975.0 | 19.66 | 1,474,008.5 | 1,576,094.0 | View | |
| Dec 05, 2025 | SVP, COMM & MEDICAL AFFAIRS | S | D | 15,534.0 | 18.7493 | 291,251.63 | 277,695.0 | View | |
| Dec 05, 2025 | SVP, COMM & MEDICAL AFFAIRS | S | D | 7,766.0 | 18.7508 | 145,618.71 | 293,229.0 | View | |
| Dec 05, 2025 | SVP, COMM & MEDICAL AFFAIRS | S | D | 7,767.0 | 18.7499 | 145,630.47 | 300,995.0 | View | |
| Dec 01, 2025 | — | M | A | 14,000.0 | 10.15 | 142,100.0 | 81,749.0 | View | |
| Dec 01, 2025 | — | S | D | 15,501.0 | 20.0 | 310,020.0 | 44,703.0 | View | |
| Dec 01, 2025 | — | S | D | 14,000.0 | 20.0 | 280,000.0 | 60,204.0 | View |